RAD140 (Testolone)

Research records

Historical source snapshot. Not freshly verified, not a recommendation. Study findings, community accounts and app defaults are not interchangeable.

Publication suitability · 2026-10-15: Historical reference only; not a clinical verification. Clinical, regulatory, efficacy, safety and dose claims are not independently established by this review.

RAD140 (Testolone)

A selective androgen receptor modulator with preclinical promise but limited human data and reported serious adverse effects.

Evidence category: Preclinical. This describes the source category, not approval or certainty.

Regulatory statement in source: Not separately recorded; do not infer approval from the evidence category.

RAD140 (Testolone) is a selective androgen receptor modulator showing potent anabolic activity in preclinical studies. Limited human research exists: six micro-dose excretion studies on five volunteers each, and a Phase I trial on metastatic breast cancer efficacy. Three published cases reported drug-induced liver damage in male users; another reported acute myocarditis.

Benefits reported in the imported source

• Selective AR binding in preclinical models; minimal prostate activation
• Neuroprotection shown in cultured neurons

Risks and limits

• Not FDA-approved; minimal human clinical data
• Three published cases of serious drug-induced liver damage
• One case of acute myocarditis and congestive heart failure
• No long-term human safety studies

Source bottom line: Preclinical promise but very limited human data; serious hepatic and cardiac adverse events reported in case studies.

Uncertainty: Reference information only. Not medical advice.

Study protocols — reports, not instructions

No study protocol recorded in this snapshot. This does not establish that no study exists.

Community and practice descriptions

Accounts of a practice are not evidence of safety or effectiveness. Words such as “standard”, “safe” or “recommended” describe the source account, not verified consensus or this wiki’s advice. Commercial and self-published citations are retained for traceability, not vendor endorsement or independent clinical corroboration.

No community description recorded. This entry has no final B-82 outcome record; it is not a researched-empty finding.

Pharmacokinetic context

Historical half-life estimate: 45–60 hours. LoRusso et al. 2022, Clin Breast Cancer 22(1):67-77, PMID 34565686 — Phase 1 human PK trial Population/route context and estimates may differ. This is not a schedule or a verified human dosing rule.

Source references

• Preclinical Assessment of RAD140 - PubMed Central
• Human In Vivo Metabolism of RAD140 - PubMed Central